Needham Reiterates Buy Rating for Definium Therapeutics
Needham maintains its bullish stance on Definium Therapeutics with a $50 price target, a 18.68% upside from the current price.
Key Points
- On June 23, 2026, Needham reiterated its buy rating for Definium Therapeutics, Inc. (DFTX) with a $50 price target.
- Needham's $50 price target implies 18.68% upside from Definium Therapeutics, Inc.'s ($DFTX) current $42.13 share price.
- Shares of NasdaqGS:DFTX traded near $36.67 on Tuesday, with a market cap of approximately $4 billion and a beta of 2.378.
- Multiple insiders, including the CEO, purchased shares on June 22, 2026, while analysts largely maintain a strong buy consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, Needham reiterated its buy rating for Definium Therapeutics, Inc. (NASDAQ: DFTX), setting a price target of $50. Shares traded near $36.67 on the same day.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Definium Therapeutics, Inc. Stock Up 2.8%
Shares of Definium Therapeutics, Inc. traded near $36.67 on Tuesday. The company, with a market cap of about $4 billion, operates in the healthcare sector, specifically in biotechnology. It has a beta of 2.378, indicating higher volatility compared to the broader market. The stock has seen a 52-week low of $6.35 and a high of $39.16. Its 50-day moving average stands at $22.61, while the 200-day moving average is $16.28. The company's financial health is underscored by a current ratio of 4.692 and a quick ratio of 4.604, with a debt-to-equity ratio of 14.622.
$DFTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Definium Therapeutics, Inc.
On June 22, 2026, several insiders at Definium Therapeutics made significant stock purchases. Chief Executive Officer Robert Barrow bought 375,000 shares. Other executives, including Chief Medical Officer Daniel Karlin and Chief Legal Officer Mark Sullivan, also acquired shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 23, 2026, Needham maintained its buy rating for Definium Therapeutics, setting a price target of $50. Other analysts have similarly expressed confidence, with Leerink Partners and Oppenheimer maintaining buy ratings with targets of $52 and $60, respectively, on June 22, 2026. The overall analyst consensus is a strong buy, with a mean target price of $39.87 based on 15 opinions.
About Definium Therapeutics
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, NY. It focuses on developing treatments for brain health disorders. The company's main products include DT120, in phase 3 trials for anxiety and depression, and DT402, in phase 2a for autism spectrum disorder. Previously known as Mind Medicine (MindMed) Inc., the company rebranded to Definium Therapeutics in January 2026. Led by CEO Robert Barrow, the company employs 105 people.
Bottom Line
Needham's reiterated buy rating with a $50 target reflects continued confidence in Definium Therapeutics, a company making strides in brain health treatments. Investors should note that analyst ratings are forward-looking opinions. With a strong buy consensus and recent insider purchases, Definium Therapeutics remains a company to watch in the biotechnology sector.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.